`Washington, D.C.
`
`
`
`
`
`
`
`In the Matter of
`
`CERTAIN PRODUCTS CONTAINING
`PYRACLOSTROBIN AND COMPONENTS
`THEREOF
`
`
`
`
`
`Investigation No. 337-TA-1303
`
`
`
`
`
`
`
`
`
`
`CONSENT ORDER
`
`The U.S. International Trade Commission (“Commission”) instituted this investigation
`
`based on a complaint filed by BASF SE of Ludwigshafen, Germany and BASF Corporation of
`
`Florham Park, New Jersey (collectively, “Complainants” or “BASF”). 87 Fed. Reg. 11730-31
`
`(Mar. 2, 2022). The complaint alleged violations of section 337 of the Tariff Act of 1930, as
`
`amended, 19 U.S.C. § 1337, based on the importation into the United States, the sale for
`
`importation, or the sale within the United States after importation of certain products containing
`
`pyraclostrobin and components thereof by reason of infringement of claims 1-17 (collectively,
`
`“the Asserted Claims”) of U.S. Patent No. 7,816,392 (“the ’392 patent” or “the Asserted
`
`Patent”).
`
`Respondent has executed a Consent Order Stipulation in which it agrees to the entry of
`
`this Consent Order and to all waivers and other provisions required by the Commission’s Rules
`
`of Practice and Procedure, 210.21(c) (19 C.F.R. § 210.21(c)).
`
`
`
`
`
`1
`
`
`
`IT IS HEREBY ORDERED THAT:
`
`1.
`
`The Complainants in this Investigation are BASF SE, a German societas europaea
`
`company organized under the laws of the European Union with headquarters and
`
`principal place of business at Carl-Bosch- Str. 38, 67056 Ludwigshafen, Germany, and
`
`BASF Corporation, a Delaware corporation with headquarters and principal place of
`
`business at 100 Campus Drive, Florham Park, New Jersey 07932.
`
`2.
`
`The Respondent covered by this Consent Order is Sharda Cropchem Ltd. (“Sharda
`
`India”), a public limited company incorporated in India with headquarters and principal
`
`place of business at Prime Business Park, 2nd Floor, Dashrathlal Joshi Road, Vile Parle
`
`(W), Mumbai, Maharashtra 400056, India.
`
`3.
`
`The Commission instituted this investigation to determine whether certain “products
`
`containing crystalline modification IV of pyraclostrobin and components thereof”
`
`(collectively, the “Subject Articles”) imported into the United States, sold for
`
`importation into the United States, and/or sold within the United States after
`
`importation infringe the Asserted Claims of the ’392 patent.
`
`4.
`
`Sharda India has executed a Consent Order Stipulation and stipulates to the entry of this
`
`Consent Order.
`
`5.
`
`Pursuant to 19 C.F.R. § 210.21(c)(4)(iii), upon the entry of this Consent Order, Sharda
`
`India shall not sell for importation, import, or sell after importation Subject Articles,
`
`directly or indirectly, and shall not aid, abet encourage, participate in, or induce the sale
`
`for importation, the importation, or the sale after importation of Subject Articles except
`
`under consent or license from BASF.
`
`
`
`2
`
`
`
`6.
`
`Pursuant to 19 C.F.R. § 210.21(c)(4)(iv), upon entry of this Consent Order, Sharda
`
`India shall not sell within the United States or otherwise transfer (except exportation)
`
`any remaining inventory of imported Subject Articles in the United States.
`
`7.
`
`Pursuant to 19 C.F.R. § 210.21(c)(4)(v), Sharda India shall cease and desist from
`
`importing and distributing the Subject Articles in the United States.
`
`8.
`
`Pursuant to 19 C.F.R. § 210.21(c)(4)(vi), Sharda India shall be precluded from seeking
`
`judicial review or otherwise challenging or contesting the validity of this Consent
`
`Order.
`
`9.
`
`Pursuant to 19 C.F.R. § 210.21(c)(4)(vii), Sharda India shall cooperate with and shall
`
`not seek to impede by litigation or other means the Commission’s efforts to gather
`
`information under Subpart I of the Commission’s Rules of Practice and Procedure, 19
`
`C.F.R. Part 210.
`
`10. Pursuant to 19 C.F.R. § 210.21(c)(4)(viii), Sharda India and its officers, directors,
`
`employees, agents, and any entity or individual acting on its behalf and with its
`
`authority shall not seek to challenge the validity or enforceability of the Asserted
`
`Claims in any administrative or judicial proceeding to enforce the Consent Order.
`
`11. Pursuant to 19 C.F.R. § 210.21(c)(4)(ix), when the ’392 patent expires, this Consent
`
`Order shall become null and void as to such.
`
`12. Pursuant to 19 C.F.R. § 210.21(c)(x), if any claim of the ’392 patent is held invalid or
`
`unenforceable by a court or agency of competent jurisdiction or if any article has been
`
`adjudicated not to infringe the asserted right in a final decision, no longer subject to
`
`appeal, this Consent Order shall become null and void as to such invalid or
`
`unenforceable claim or adjudicated article.
`
`
`
`3
`
`
`
`13. Pursuant to 19 C.F.R. § 210.21(c)(4)(xi), Sharda India has admitted that the
`
`Commission has in rem jurisdiction over Subject Articles that are the basis of this
`
`Investigation, in personam jurisdiction over Sharda India for the purposes of this
`
`Consent Oder, and subject matter jurisdiction over this Investigation.
`
`14. Pursuant to 19 C.F.R. § 210.21(c)(xii), this Investigation is hereby terminated;
`
`provided, however, that enforcement, modification, or revocation of the Consent Order
`
`shall be carried out pursuant to Subpart I of the Commission’s Rules of Practice and
`
`Procedure, 19 C.F.R. part 210.
`
`By order of the Commission.
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Issued: April 12, 2022
`
`Lisa R. Barton
`Secretary to the Commission
`
`
`
`4
`
`